| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-08 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-08 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | 0.19 | 1e-07 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.57 | 3e-07 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-06 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.28 | 2e-06 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-06 |
| mRNA | decitabine:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-06 |